McFarlane Neil F. 4

4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 10, 2026

AI-generated summary of this filing

Updated Feb 10, 2026

Zevra CEO Neil McFarlane Exercises RSUs, Sells 14,625 Shares

What Happened

Neil F. McFarlane, President, CEO and Director of Zevra Therapeutics, had one-third of a restricted stock unit (RSU) award vest and settle on Feb 7, 2026. The filing reports 37,500 shares acquired and 37,500 shares disposed at $0 (reflecting withholding/surrender to satisfy tax obligations), for a total of 75,000 shares involved in the vesting/settlement.
On Feb 9, 2026, McFarlane sold 14,625 shares in the open market under a pre-existing 10b5-1 trading plan, at a weighted average price of $8.56 per share, generating proceeds of $125,186.

Key Details

Transaction dates: Feb 7, 2026 (RSU vesting/conversion); Feb 9, 2026 (open-market sale).
Sale price/details: 14,625 shares sold at a weighted average of $8.56; trades ranged $8.39–$8.67 (per filing footnote).
Proceeds: $125,186 from the open-market sale.
Vesting schedule: Footnote states one-third vested/settled on Feb 7, 2026; the remaining two-thirds vest and settle in two equal annual installments thereafter, subject to continued service.
10b5-1 plan: Sale executed under a 10b5-1 plan adopted 3/21/2025 (per footnote).
Shares owned after transaction: Not specified in the excerpt provided.
Filing: Report filed Feb 10, 2026, covering the Feb 7 and Feb 9 transactions (no late-filing indicator shown in the provided excerpt).

Context

The Feb 7 entries reflect conversion/settlement of RSUs (derivative code M) with a portion of shares withheld or surrendered to cover taxes (reported as a $0 disposition).
The Feb 9 sale was executed under a pre-established trading plan (10b5-1); such plans regularly govern timing and execution of insider sales and are disclosed in the filing.
The filing is factual about the transactions; it does not state the insider’s motivations.

Form 4

Period: 2026-02-07

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-07+37,500→ 401,850 total
Sale
Common Stock
[F2][F3]
2026-02-09$8.56/sh−14,625$125,186→ 387,225 total
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-02-07−37,500→ 75,000 total
→ Common Stock (37,500 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]Adoption date of referenced 10b5-1(c) plan is: 3/21/2025.
[F3]This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Signature

/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane|2026-02-10

1 file